Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Netilmicin Sulfate

FDA-approved product (injectable, injection), marketed as Netromycin.

Registered studies
4
Lab records
14
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Netilmicin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other aminoglycosides; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB07; WHO ATC S01AA23

Repurposing investigation

Netilmicin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae91.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

4registered studies name this medicine, for any condition. See them below.

Experimental

  • E. coli: measured active in 2 of 3 lab records
  • K. pneumoniae: measured active in 7 of 11 lab records
Open Netilmicin Sulfate in ChEMBL Registered studies below
Show the 14 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Netilmicin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction

    NCT02973880 · start 2017-10-15

    Registered record
    Registry ID
    NCT02973880
    Conditions
    Cataract Extraction; Cataract
    Interventions
    NETILDEX™ ophthalmic gel; NETILDEX™ eye drops solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-15
    Completion
    2018-12-30
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract Extraction; Cataract
    InterventionNETILDEX™ ophthalmic gel; NETILDEX™ eye drops solution
    PhasePhase 3
    Registry statusCompleted

  • Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus

    NCT02701595 · start 2016-02-29

    Registered record
    Registry ID
    NCT02701595
    Conditions
    Infective Endocarditis
    Interventions
    Amoxicillin; Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-29
    Completion
    2023-06-24
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfective Endocarditis
    InterventionAmoxicillin; Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
    PhasePhase 3
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment

    NCT01559753 · start 1998-01

    Registered record
    Registry ID
    NCT01559753
    Conditions
    Pneumonia Ventilator Associated
    Interventions
    Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1998-01
    Completion
    2002-11
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia Ventilator Associated
    InterventionAugmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatment
    PhasePhase 4
    Registry statusCompleted